Emerging targeted therapies for plaque psoriasis – Impact of ixekizumab

Clinical, Cosmetic and Investigational Dermatology

Volumn 10, Issue , 2017, Pages 133-139

  Kazemi, Tiana ^a   Farahnik, Benjamin ^b   Koo, John ^c   Beroukhim, Kourosh ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biologic medication; IL 12; IL 17; IL 23; Ixekizumab; Psoriasis

Indexed keywords

BRODALUMAB; ETANERCEPT; GUSELKUMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; IXEKIZUMAB; SECUKINUMAB; TILDRAKIZUMAB; USTEKINUMAB;

ARTHRALGIA; ASSESSMENT OF HUMANS; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIOLOGICAL DATA; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; MOLECULARLY TARGETED THERAPY; OCCUPATION AND OCCUPATION RELATED PHENOMENA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN GLOBAL ASSESSMENT; PSORIASIS AREA AND SEVERITY INDEX 75; PSORIASIS VULGARIS; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; WORK PRODUCTIVITY;

EID: 85020541224     PISSN: None     EISSN: 11787015     Source Type: Journal    
DOI: 10.2147/CCID.S111007     Document Type: Review

References (37)

1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
2. Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol. 2007;25(6):524–528.
3. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–1199.
4. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007;9(6):461–467.
5. Canavan TN, Elmets CA, Cantrell WL, Evans JM, Elewski BE. Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2016;17(1):33–47.
6. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18): 1899–1912.
7. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17–26.
8. Ariza ME, Williams MV, Wong HK. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application. Clin Immunol. 2013;146(2):131–139.
9. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130(5):1373–1383.
10. Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007;8(6):639–646.
11. Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204(8):1849–1861.
12. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207–1211.
13. Krueger JG, Fretzin S, Suarez-Farinas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145–154. e9.
14. Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat. 2003;14(3):158–165.
15. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659–664.
16. Papp K, Thaci D, Reich K, et al. Tildrakizumab (MK-3222), an antiinterleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4): 930–939.
17. Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2): 136–144.
18. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625): 1675–1684.
19. Karen Riley. FDA approves new drug to treat psoriasis. US Food and Drug Administration. 25 September 2009. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ ucm183851.htm. Accessed 25 July 2016.
20. Farahnik B, Beroukhim K, Abrouk M, et al. Brodalumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther (Heidelb). 2016;6(2):111–124.
21. Farahnik B, Beroukhim K, Nakamura M, et al. Anti-IL-17 agents for psoriasis: a review of phase III data. J Drugs Dermatol. 2016;15(3): 311–316.
22. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14): 1318–1328.
23. Trish Hawkins. Amgen to Terminate Participation in Co-development and Commercialization of Brodalumab. Amgen Press Release. Amgen, 22 May 2015. Available from: http://www.prnewswire.com/news-releases/amgen-to-terminate-participation-in-co-development-and-commercial ization-of-brodalumab-300088098.html. Accessed 25 July 2016.
24. Papp K, Reich K, Leonardi C, et al. Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: results of AMAGINE-1, a phase 3, randomized, double-blind, placebo-controlled study through week JAAD. 2015;72(5):AB233.
25. Langley RG, Elewski BE, Lebwohl M, et al; ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
26. Blauvelt A, Prinz JC, Gottlieb AB, et al; FEATURE Study Group. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–493.
27. Paul C, Lacour JP, Tedremets L, et al; JUNCTURE study group. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–1090.
28. MacGregor JS. Lilly’s Ixekizumab Superior to Etanercept and Placebo in Phase 3 Psoriasis Studies. Eli Lilly and Company, Indianapolis. 2014. Available from: https://investor.lilly.com/releasedetail.cfm?releaseid=867193. Accessed 25 July 2016.
29. FDA approves new psoriasis drug Taltz. US Food and Drug Administration. 22 March 2016.Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491872.htm. Accessed 25 July 2016.
30. Gordon K. Ixekizumab for Treatment of Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Double-Blind Phase 3 Induction and Randomized Withdrawal Study (UNCOVER-1).pdf. 2015.
31. Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(21):2102.
32. Griff iths CE, Reich K, Lebwohl M, et al; UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386(9993):541–551.
33. Armstrong AW, Lynde CW, McBride SR, et al. Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials. JAMA Dermatol. 2016;152(6):661–669.
34. Bhutani T, Patel T, Koo B, Nguyen T, Hong J, Koo J. A prospective, interventional assessment of psoriasis quality of life using a nonskinspecific validated instrument that allows comparison with other major medical conditions. J Am Acad Dermatol. 2013;69(2):e79–e88.
35. Feldman SR, Malakouti M, Koo JY. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J. 2014; 20(8).
36. Wu JJ, Poon K-YTY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch. Dermatol. 2012;148(11): 1244–1250.
37. Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409.